Abstract
Introduction: This study aims to evaluate the efficacy and safety of cryoablation combined with pembrolizumab treatment versus cryoablation alone in patients with advanced non-small cell lung cancer (NSCLC). Methods: This retrospective study was conducted from February 2018 to October 2021. A total of 90 patients with NSCLC (AJCC stage IIIB/IV) were included, with 36 patients receiving cryoablation combined with pembrolizumab (group A) and 54 patients receiving cryoablation alone (group B). The primary outcome measures included objective response rate (ORR), overall survival (OS), and progression-free survival (PFS), immune responses, and adverse events serving as secondary endpoints. Risk factors for OS and PFS were identified using univariate and multivariate analyses. Results: No treatment-related deaths were observed. Group A demonstrated a higher ORR (75.0% vs. 61.1%), longer median OS (28.1 months vs. 24.2 months), and longer median PFS (12.8 months vs. 8.4 months) compared to Group B. Additionally, group A showed significant increases in CD3+, CD4+, and CD8+ T cells, and elevated levels of interleukin-2, interleukin-6, TNF-β, and interferon-γ. The multivariate analysis showed the combination of cryoablation and pembrolizumab was an independent prognostic factor for OS and PFS. Conclusions: Cryoablation combined with pembrolizumab significantly improves clinical outcomes in advanced NSCLC patients compared to cryoablation alone, highlighting the potential of this combination therapy in enhancing antitumor immunity and prolonging survival.
Journal Section:
Anticancer
References
1.
Siegel
RL
, Giaquinto
AN
, Jemal
A
. Cancer statistics, 2024
. CA Cancer J Clin
. 2024
;74
(1
):12
–49
. 2.
Herbst
RS
, Morgensztern
D
, Boshoff
C
. The biology and management of non-small cell lung cancer
. Nature
. 2018
;553
(7689
):446
–54
. 3.
Jonna
S
, Subramaniam
DS
. Molecular diagnostics and targeted therapies in non-small cell lung cancer (nsclc): an update
. Discov Med
. 2019
;27
(148
):167
–70
.4.
Tang
S
, Qin
C
, Hu
H
, Liu
T
, He
Y
, Guo
H
, et al. Immune checkpoint inhibitors in non-small cell lung cancer: progress, challenges, and prospects
. Cells
. 2022
;11
(3
):320
. 5.
Chen
R
, Manochakian
R
, James
L
, Azzouqa
A-G
, Shi
H
, Zhang
Y
, et al. Emerging therapeutic agents for advanced non-small cell lung cancer
. J Hematol Oncol
. 2020
;13
(1
):58
. 6.
Leung
EL-H
, Fan
X-X
, Huang
J-M
, Huang
C
, Lin
H
, Cao
Y-B
. Holistic immunomodulation for small cell lung cancer
. Semin Cancer Biol
. 2023
;88
:96
–105
. 7.
Yan
N
, Guo
S
, Zhang
H
, Zhang
Z
, Shen
S
, Li
X
. Braf-mutated non-small cell lung cancer: current treatment status and future perspective
. Front Oncol
. 2022
;12
:863043
. 8.
Xu
Z
, Wang
X
, Ke
H
, Lyu
G
. Cryoablation is superior to radiofrequency ablation for the treatment of non-small cell lung cancer: a meta-analysis
. Cryobiology
. 2023
;112
:104560
. 9.
Lin
W-C
, Chen
P-J
, Yim
S
, Wang
H-H
, Liao
P-A
, Tai
C-Y
, et al. The safety and response of ct guided percutaneous cryoablation for lung nodules by 17-gauge needles
. BMC Med Imaging
. 2023
;23
(1
):151
. 10.
Sänger
JA
, Graur
A
, Tahir
I
, Price
MC
, Keane
FK
, Lanuti
M
, et al. Outcomes following cryoablation of stage ia non-small cell lung cancer in patients with and without interstitial lung disease: a retrospective single-center cohort study
. Lung Cancer
. 2023
;181
:107231
. 11.
Velez
A
, DeMaio
A
, Sterman
D
. Cryoablation and immunity in non-small cell lung cancer: a new era of cryo-immunotherapy
. Front Immunol
. 2023
;14
:1203539
. 12.
Gu
C
, Wang
X
, Wang
K
, Xie
F
, Chen
L
, Ji
H
, et al. Cryoablation triggers type I interferon-dependent antitumor immunity and potentiates immunotherapy efficacy in lung cancer
. J Immunother Cancer
. 2024
;12
(1
):e008386
. 13.
Wu
Y
, Cao
F
, Zhou
D
, Chen
S
, Qi
H
, Huang
T
, et al. Cryoablation reshapes the immune microenvironment in the distal tumor and enhances the anti-tumor immunity
. Front Immunol
. 2022
;13
:930461
. 14.
Grasso
RF
, Luppi
G
, Cazzato
RL
, Del Vescovo
R
, Giurazza
F
, Mercurio
S
, et al. Cryoablation of lung malignancies recurring close to surgical clips following surgery: report of three cases
. Indian J Radiol Imaging
. 2015
;25
(1
):11
–4
. 15.
Garon
EB
, Rizvi
NA
, Hui
R
, Leighl
N
, Balmanoukian
AS
, Eder
JP
, et al. Pembrolizumab for the treatment of non-small-cell lung cancer
. N Engl J Med
. 2015
;372
(21
):2018
–28
. 16.
Garon
EB
, Hellmann
MD
, Rizvi
NA
, Carcereny
E
, Leighl
NB
, Ahn
M-J
, et al. Five-year overall survival for patients with advanced non‒small-cell lung cancer treated with pembrolizumab: results from the phase I keynote-001 study
. J Clin Oncol
. 2019
;37
(28
):2518
–27
. 17.
Reck
M
, Rodríguez-Abreu
D
, Robinson
AG
, Hui
R
, Csőszi
T
, Fülöp
A
, et al. Pembrolizumab versus chemotherapy for Pd-L1-Positive non-small-cell lung cancer
. N Engl J Med
. 2016
;375
(19
):1823
–33
. 18.
Novello
S
, Kowalski
DM
, Luft
A
, Gümüş
M
, Vicente
D
, Mazières
J
, et al. Pembrolizumab plus chemotherapy in squamous non-small-cell lung cancer: 5-year update of the phase iii keynote-407 study
. J Clin Oncol
. 2023
;41
(11
):1999
–2006
. 19.
Gandhi
L
, Rodríguez-Abreu
D
, Gadgeel
S
, Esteban
E
, Felip
E
, De Angelis
F
, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer
. N Engl J Med
. 2018
;378
(22
):2078
–92
. 20.
Grasso
RF
, Luppi
G
, Cazzato
RL
, Faiella
E
, D’Agostino
F
, Beomonte Zobel
D
, et al. Percutaneous computed tomography-guided lung biopsies: preliminary results using an augmented reality navigation system
. Tumori
. 2012
;98
(6
):775
–82
. 21.
Grasso
RF
, Cazzato
RL
, Luppi
G
, D’Agostino
F
, Schena
E
, Del Vescovo
R
, et al. Percutaneous lung biopsies: performance of an optical CT-based navigation system with a low-dose protocol
. Eur Radiol
. 2013
;23
(11
):3071
–6
. 22.
Grasso
RF
, Andresciani
F
, Altomare
C
, Pacella
G
, Castiello
G
, Carassiti
M
, et al. Lung thermal ablation: comparison between an augmented reality computed tomography (CT) 3d navigation system (sirio) and standard CT-guided technique
. Biology
. 2021
;10
(7
):646
. 23.
Grasso
RF
, Faiella
E
, Luppi
G
, Schena
E
, Giurazza
F
, Del Vescovo
R
, et al. Percutaneous lung biopsy: comparison between an augmented reality CT navigation system and standard CT-guided technique
. Int J Comput Assist Radiol Surg
. 2013
;8
(5
):837
–48
. 24.
Eisenhauer
EA
, Therasse
P
, Bogaerts
J
, Schwartz
LH
, Sargent
D
, Ford
R
, et al. New response evaluation criteria in solid tumours: revised recist guideline (version 1.1)
. Eur J Cancer
. 2009
;45
(2
):228
–47
. 25.
Herbst
RS
, Garon
EB
, Kim
D-W
, Cho
BC
, Perez-Gracia
JL
, Han
J-Y
, et al. Long-term outcomes and retreatment among patients with previously treated, programmed death-ligand 1‒positive, advanced non‒small-cell lung cancer in the keynote-010 study
. J Clin Oncol
. 2020
;38
(14
):1580
–90
. 26.
Sabel
MS
, Su
G
, Griffith
KA
, Chang
AE
. Rate of freeze alters the immunologic response after cryoablation of breast cancer
. Ann Surg Oncol
. 2010
;17
(4
):1187
–93
. 27.
Yu
Z
, Wang
D
, Qi
Y
, Liu
J
, Zhou
T
, Rao
W
, et al. Autologous-cancer-cryoablation-mediated nanovaccine augments systematic immunotherapy
. Mater Horiz
. 2023
;10
(5
):1661
–77
. 28.
den Brok
MHMGM
, Sutmuller
RPM
, Nierkens
S
, Bennink
EJ
, Toonen
LWJ
, Figdor
CG
, et al. Synergy between in situ cryoablation and Tlr9 stimulation results in a highly effective in vivo dendritic cell vaccine
. Cancer Res
. 2006
;66
(14
):7285
–92
. 29.
Seguin
J
, El Hajjam
M
, Legagneux
J
, Diakhaby
S
, Mignet
N
, Boudy
V
, et al. Radiofrequency combined with intratumoral immunotherapy: preclinical results and safety in metastatic colorectal carcinoma
. Pharmaceutics
. 2024
;16
(3
):315
. 30.
Wang
J
, Zong
D
, Dong
S
, Gao
S
, Yang
Y
, Zhang
P
, et al. Argon-helium knife cryoablation plus programmed cell death protein 1 inhibitor in the treatment of advanced soft tissue sarcomas: there is no evidence of the synergistic effects of this combination therapy
. Front Oncol
. 2023
;13
:1185291
. 31.
Brahmer
J
, Reckamp
KL
, Baas
P
, Crinò
L
, Eberhardt
WEE
, Poddubskaya
E
, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer
. N Engl J Med
. 2015
;373
(2
):123
–35
. 32.
Brahmer
JR
, Tykodi
SS
, Chow
LQM
, Hwu
W-J
, Topalian
SL
, Hwu
P
, et al. Safety and activity of anti-Pd-L1 antibody in patients with advanced cancer
. N Engl J Med
. 2012
;366
(26
):2455
–65
. 33.
Wang
J
, Ge
H
, Tian
Z
. Immunotherapy plus radiotherapy for the treatment of sarcomas: is there a potential for synergism
. Onco Targets Ther
. 2023
;16
:385
–97
. © 2025 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
You do not currently have access to this content.
